The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results from a randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy (REASON).
C. Lhomme
No relevant relationships to disclose
D. Berton-Rigaud
No relevant relationships to disclose
F. Joly
No relevant relationships to disclose
J. Baurain
No relevant relationships to disclose
F. Rolland
No relevant relationships to disclose
A. Stenzl
No relevant relationships to disclose
T. Schmelter
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
M. Campone
No relevant relationships to disclose